Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial
· Targovax and Agenus have entered into a clinical collaboration agreement for the ONCOS-102 melanoma phase 2 multi-cohort trial · ONCOS-102 will be tested in combination with the two checkpoint inhibitors balstilimab (anti-PD1) and botensilimab (second generation anti-CTLA4) in patients with anti-PD1 refractory malignant melanomaOslo, Norway, 11 May 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has entered into a clinical collaboration and supply agreement with Agenus